February 2024
SkIN Canada News
Canadian Skin Research Conference June 25-27, 2024 in Ottawa
A joint meeting of the Skin Investigators Network of Canada (SkIN Canada), Skin Research Group of Canada (SRGC), Canadian Dermatology Foundation (CDF), Canadian Skin Patient Alliance (CSPA), and Canadian Society for Investigative Dermatology (CSID), will be held in conjunction with the 99th Canadian Dermatology Association (CDA) Annual Conference.
2023 Team Development Award Recipients (New Awards)
Aaron Drucker
2023 Team Development Award Recipients (New Awards)
Regine Mydlarski
2023 Team Development Award Recipients (New Awards)
Brett Thombs
2023 Team Development Award Recipients (New Awards)
Mina Tadrous
2023 Team Development Award Recipients (New Awards)
Maryam Piram
2023 Team Development Award Recipients (Renewals)
Caitlin Champion
2023 Team Development Award Recipients (Renewals)
Carolyn Jack
2023 Team Development Award Recipients (Renewals)
Elena Netchiporouk
2023 Team Development Award Recipients (Renewals)
Lucie Germain
2023 Team Development Award Recipients (Renewals)
Mélanie Laurin
2023 Team Development Award Recipients (Renewals)
Timothy Hanna
Can SkIN Canada help? Request support for your study
SkIN Canada has launched a formal study intake process for investigators requesting support from the Network. Please visit our RESOURCES page for more information on how we can help with funding, patient engagement, database creation, project administration, ethics application, or statistical support.
From the Training Committee Hub
Skin Canada Travel and Mobility Awards – Application Deadline May 15, 2024
1. The deadline for the next SkIN Canada Trainee Travel Award is Wednesday May 15 (2024) before 11:59 PM ET. SkIN Canada provides partial funding for trainees to attend conferences as part of their training experience. A limited number of awards are available each year on a competitive basis. Applicants who have previously received funding through this program in a fiscal year are not eligible to receive funding until the following fiscal year. The value of the SkIN Canada Travel Award is a maximum of $1,000 CAD.
2. The deadline for the next SkIN Canada Trainee Mobility Award is Wednesday May 15 (2024) before 11:59 PM ET. The SkIN Canada Trainee Mobility Award provides funding for trainees in the field of skin research to study and conduct research for a brief period in a laboratory other than their own within Canada or abroad as part of their training experience. A limited number of awards are available each year on a competitive basis. There will be two competition periods per year, one in May and one in October. Applicants are eligible for the award only once during a particular training period or level of study (e.g. MSc, PhD, Clinical residency, or Postdoctoral training).
The value of the Skin Canada Trainee Mobility Award is up to $4,000 which can be used for the trainee’s research in a host laboratory within Canada or abroad for a period ranging from 2 weeks to 6 months.
Skin Canada Training Committee
The Training Committee represents skin research trainees from across Canada and considers regional representation to be valuable. The committee currently has an opening for a PhD student or a post-doctoral fellow from any of the Western Provinces. If interested in joining this dynamic committee, please send your expression of interest and CV to info@skincanada.org.
Workshops of Interest to Skin Research Trainees
The Annual Skin Canada Workshops will be held at the upcoming Canadian Skin Research Conference in Ottawa (June 25-27, 2024). The workshop topics will include ‘patient engagement’ and ‘Skin of Color Research’. All trainees are encouraged to participate. There is no registration fee.
The next SkIN Canada Training Committee Meeting will be held on Thursday March 21st.
News from other Organizations Genodermatoses Network Meeting
Open Call: Participation in Project on Indigenous Patients with Atopic Dermatitis
This is an open call for those interested in helping to develop a proposal involving formation of a national east-west collaborative interdisciplinary engagement initiative and culturally safe model aiming to improve care for Canadian Indigenous peoples living with or caring for those with atopic dermatitis. Co-PIs include Drs. Rachel Asiniwasis (University of Saskatchewan), Carolyn Jack (McGill), and Derek Chu (McMaster).
Please forward your CV to remotederm@outlook.com, particularly if you have experience with:
• public and community health
• qualitative and mixed-methods research
• CIHR grant writing
• Indigenous health and skin of colour
• using guidelines involving meaningful and culturally safe practices and plans.
The team is also looking for another Co-PI from BC or Alberta.
Keen-on Healing Fibrosis Symposium – October 18-19 2024
Request for Standing Offers: Post-Market Drug Evaluation Program
Canada’s Drug and Health Technology Agency (CADTH) has a Post-Market Drug Evaluation Program (PMDE) that focuses on providing answers to questions about the safety and effectiveness of drugs, whether they are existing or new products. The program has been designed to maximize CADTH’s access to a wide range of applied researchers, data analysts, and methodologists from across Canada. To meet future needs, the PMDE program has launched a Request for Standing Offers process to recruit more individuals and teams to join CoLab, their network of researchers.
Pfizer Global Medical Grants – Request for Proposals
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on educational programs addressing knowledge and practice gaps specific to the overall care management of atopic dermatitis (AD), Alopecia Areata (AA), or Vitilgo. If you have questions regarding this RFP, please direct them in writing to Sue Lee, Grant Officer (sue.lee@pfizer.com). Application Due Date: Monday April 15, 2024.
Recent Publications by SkIN Canada Members
Inflammatory Skin Conditions
1.
Hundal S, Cappelli J, Croitoru D. Hundal S, Cappelli J, Croitoru D, et al. Cost-Utility Analysis of Clinic-Based Deroofing versus Local Excision for Hidradenitis Suppurativa. J Am Acad Dermatol. Dec 8 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39657847
2.
Vallee S, Deneux V, Funaro D. Vallee S, Deneux V, Funaro D, et al. Long-term evolution of prepubertal-onset anogenital lichen sclerosus: A 35-year retrospective and cross-sectional study from a single tertiary care maternal and pediatric center. J Am Acad Dermatol. Dec 3 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39637982
3.
Eichenfield LF, Hebert AA, Harper JC. Eichenfield LF, Hebert AA, Harper JC, et al. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents. J Drugs Dermatol. Dec 1 2024;23(12):1049-1057..
https://www.ncbi.nlm.nih.gov/pubmed/39630680
4.
Armstrong AW, Bissonnette R, Chovatiya R. Armstrong AW, Bissonnette R, Chovatiya R, et al. Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis. Cutis. Oct 2024;114(4):122-127..
https://www.ncbi.nlm.nih.gov/pubmed/39621574
5.
Choi UE, Deng J, Parthasarathy V. Choi UE, Deng J, Parthasarathy V, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol. Nov 28 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39615548
Wound Healing, Fibrosis and Regeneration
1.
Bian X, Piipponen M, Liu Z. Bian X, Piipponen M, Liu Z, et al. Epigenetic memory of radiotherapy in dermal fibroblasts impairs wound repair capacity in cancer survivors. Nature communications. Oct 28 2024;15(1):9286..
https://www.ncbi.nlm.nih.gov/pubmed/39468077
2.
Arif S, Larochelle S, Trudel B. Arif S, Larochelle S, Trudel B, et al. The diffusion of normal skin wound myofibroblast-derived microvesicles differs according to matrix composition. J Extracell Biol. Jan 2024;3(1):e131..
https://www.ncbi.nlm.nih.gov/pubmed/38938680
3.
Arif S, Larochelle S, Trudel B. Arif S, Larochelle S, Trudel B, et al. The diffusion of normal skin wound myofibroblast-derived microvesicles differs according to matrix composition. J Extracell Biol. Jan 2024;3(1):e131..
https://www.ncbi.nlm.nih.gov/pubmed/38938680
4.
Arif S, Richer M, Larochelle S, Moulin VJ. Arif S, Richer M, Larochelle S, Moulin VJ. Microvesicles derived from dermal myofibroblasts modify the integrity of the blood and lymphatic barriers using distinct endocytosis pathways. J Extracell Biol. May 2024;3(5):e151..
https://www.ncbi.nlm.nih.gov/pubmed/38939570
5.
Rijal H, Bouadi N, Piguet V, Mukovozov I. Rijal H, Bouadi N, Piguet V, Mukovozov I. Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review. J Cutan Med Surg. Jun 10 2024:12034754241260021..
https://www.ncbi.nlm.nih.gov/pubmed/38859662
Skin Cancer
1.
Guerra Ordaz DJ, Whitelaw S, Kaouache M. Guerra Ordaz DJ, Whitelaw S, Kaouache M, et al. Evaluating the Implementation and Impact of BRAF Reflex Mutation Testing in Melanoma, Lung, and Colorectal Cancers. J Cutan Med Surg. Dec 4 2024:12034754241302821..
https://www.ncbi.nlm.nih.gov/pubmed/39629857
2.
Koulmi K, Cattelan L, Litvinov IV. Koulmi K, Cattelan L, Litvinov IV. Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review. J Cutan Med Surg. Nov 30 2024:12034754241302818..
https://www.ncbi.nlm.nih.gov/pubmed/39614759
3.
Huang Y, Fleming P, Fung K, Chan AW. Huang Y, Fleming P, Fung K, Chan AW. Response to Tang et al., “Insufficient evidence for association between dermatology follow-up and melanoma survival”. J Am Acad Dermatol. Nov 21 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39579995
4.
Ma B, James MT, Chan AW, Mydlarski PR. Ma B, James MT, Chan AW, Mydlarski PR. National Trends in Healthcare Expenditures for the Management of Skin Cancer in the United States. J Cutan Med Surg. Nov 16 2024:12034754241293131..
https://www.ncbi.nlm.nih.gov/pubmed/39548853
5.
Karponis D, Joshy J, Stratigos IA. Karponis D, Joshy J, Stratigos IA, et al. Cutaneous melanoma in situ: a review. Clin Exp Dermatol. Oct 25 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39449583
Skin of Colour
1.
Moy AP, Zhou D, Chen J, White C, Riedel ER, Pulitzer MP. Moy AP, Zhou D, Chen J, White C, Riedel ER, Pulitzer MP. Merkel Cell Carcinoma among non-Caucasian patients: a retrospective case-control study. J Am Acad Dermatol. Apr 23 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/38663746
2.
Cedirian S, Starace M, Natale A. Cedirian S, Starace M, Natale A, et al. Celebrating Diversity: Unveiling the Characteristics of Nail Psoriasis and Nail Lichen Planus in 30 Patients With Skin of Color. Dermatol Pract Concept. Oct 30 2024;14(4).
https://www.ncbi.nlm.nih.gov/pubmed/39652925
3.
Greene A, Ghalambor T, Penner S, Irwin C, Hastings KT. Greene A, Ghalambor T, Penner S, Irwin C, Hastings KT. Evaluation of dermatologic diagnostic ability on skin of colour in preclinical medical students. Skin Health Dis. Dec 2024;4(6):e425..
https://www.ncbi.nlm.nih.gov/pubmed/39624754
4.
Elhassan H. Elhassan H. Considerations for Physicians Treating Skin of Color: A Narrative Review. Cureus. Nov 2024;16(11):e74443..
https://www.ncbi.nlm.nih.gov/pubmed/39606129
5.
Lee M, Brown LS, Sontheimer R, Chong BF. Lee M, Brown LS, Sontheimer R, Chong BF. Distinctive clinical features are found in dermatomyositis patients with skin of color. Arch Dermatol Res. Nov 26 2024;317(1):48..
https://www.ncbi.nlm.nih.gov/pubmed/39589527
Other
1.
Hedtrich S, Calderon M. Hedtrich S, Calderon M. Next generation concepts in dermal delivery, theranostics, and preclinical testing. Adv Drug Deliv Rev. Nov 29 2024:115482..
https://www.ncbi.nlm.nih.gov/pubmed/39617255
2.
Coughlan K, Purvis T, Kilkenny MF. Coughlan K, Purvis T, Kilkenny MF, et al. From ‘strong recommendation’ to practice: A pre-test post-test study examining adherence to stroke guidelines for fever, hyperglycaemia, and swallowing (FeSS) management post-stroke. Int J Nurs Stud Adv. Dec 2024;7:100248..
https://www.ncbi.nlm.nih.gov/pubmed/39507681
3.
Gupta AK, Talukder M, Piguet V. Gupta AK, Talukder M, Piguet V. Mpox: A Rising Threat-2 Public Health Emergencies in 2 Years. The Journal of investigative dermatology. Oct 21 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39436346
4.
Dinesh NEH, Rousseau J, Mosher DF. Dinesh NEH, Rousseau J, Mosher DF, et al. Mutations in fibronectin dysregulate chondrogenesis in skeletal dysplasia. Cellular and molecular life sciences : CMLS. Oct 5 2024;81(1):419..
https://www.ncbi.nlm.nih.gov/pubmed/39367925
5.
Savard E, Magne B, Simard-Bisson C. Savard E, Magne B, Simard-Bisson C, et al. Design of an innovative method for measuring the contractile behaviour of engineered tissues. Tissue engineering Part C, Methods. Sep 23 2024;.
https://www.ncbi.nlm.nih.gov/pubmed/39311467
Contact Us | Visite skincanada.org
SkIN Canada Executive Committee
